Kezar Life Sciences (KZR)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 15, 2022, Kezar Life Sciences, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2022.
Proposal 1: The Company’s stockholders elected the three nominees of the Company’s board of directors to serve as Class I directors until the 2025 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below:
NomineeVotes ForVotes WithheldBroker Non-Votes
Elizabeth Garner, M.D.32,387,89817,784,3926,007,767
Michael Kauffman, M.D., Ph.D.29,866,60720,305,6836,007,767
Courtney Wallace45,460,0154,712,2756,007,767
Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 by the votes set forth in the table below:
Votes ForVotes AgainstAbstain